For Ed, a longer life meant more time with family, friends and his dog, BearBear. When he was diagnosed with colon cancer, he underwent six weeks of radiation, seven months of chemotherapy and 10 surgeries. But today, he is cancer free.
For Roxanne, a healthier life meant pursuing her dream of going to culinary school after a silent heart attack 10 years ago. Today, she isn’t missing a beat, thanks to two lifesaving medicines that keep her heart healthy.
For both of these patients, a longer, healthier life was and continues to be possible thanks to innovative medicines.
Their lives, like the lives of millions of patients, are stories told fondly with hope for the future. Each day, hundreds of thousands of scientists and researchers are fighting tirelessly to develop new treatments and cures for patients. And thanks to the perseverance of these men and woman at America’s biopharmaceutical companies, patients and families have an opportunity to lead longer lives.
Ed and Roxanne are just two examples of individuals who have fought against disease, thanks in large part to innovative medicines. In 2016, PhRMA’s “From Hope to Cures” campaign is highlighting the value biopharmaceutical research is contributing to the development of innovative treatments and cures for patients, society and the economy. In addition to sharing real stories from patients and researchers, the campaign also highlights data and information on fighting disease, clinical trials and the economic contributions from the biopharmaceutical industry.
Highlighting the innovation and promise of medicines in development is critical to fostering the development of tomorrow’s treatments and cures. Explore Patients, Science, Health Care and Economy to better understand the ecosystem of innovation in the biopharmaceutical industry.
Learn more here about the campaign and how America’s biopharmaceutical companies are driving innovation, collaborating and helping to translate new findings into hope for America’s patients.
View the campaign’s multimedia news release here.